↓ Skip to main content

Dove Medical Press

Article Metrics

Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke

Overview of attention for article published in Vascular Health and Risk Management, February 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#44 of 404)
  • High Attention Score compared to outputs of the same age (84th percentile)
  • High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

blogs
1 blog
twitter
1 tweeter

Citations

dimensions_citation
60 Dimensions

Readers on

mendeley
88 Mendeley
Title
Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke
Published in
Vascular Health and Risk Management, February 2014
DOI 10.2147/vhrm.s39213
Pubmed ID
Authors

Karen Johnston, Sherita Chapman, Prachi Mehndiratta, Michelle Johansen, Andrew Southerland, Timothy McMurry

Abstract

In 1995, the NINDS (National Institute of Neurological Disorders and Stroke) tPA (tissue plasminogen activator) Stroke Study Group published the results of a large multicenter clinical trial demonstrating efficacy of intravenous tPA by revealing a 30% relative risk reduction (absolute risk reduction 11%-15%) compared with placebo at 90 days in the likelihood of having minimal or no disability. Since approval in 1996, tPA remains the only drug treatment for acute ischemic stroke approved by the US Food and Drug Administration. Over the years, an abundance of research and clinical data has supported the safe and efficacious use of intravenous tPA in all eligible patients. Despite such supporting data, it remains substantially underutilized. Challenges to the utilization of tPA include narrow eligibility and treatment windows, risk of symptomatic intracerebral hemorrhage, perceived lack of efficacy in certain high-risk subgroups, and a limited pool of neurological and stroke expertise in the community. With recent US census data suggesting annual stroke incidence will more than double by 2050, better education and consensus among both the medical and lay public are necessary to optimize the use of tPA for all eligible stroke patients. Ongoing and future research should continue to improve upon the efficacy of tPA through more rapid stroke diagnosis and treatment, refinement of advanced neuroimaging and stroke biomarkers, and successful demonstration of alternative means of reperfusion.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 88 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 2 2%
Switzerland 1 1%
Saudi Arabia 1 1%
Unknown 84 95%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 18 20%
Student > Master 14 16%
Researcher 11 13%
Student > Ph. D. Student 11 13%
Other 8 9%
Other 21 24%
Unknown 5 6%
Readers by discipline Count As %
Medicine and Dentistry 36 41%
Agricultural and Biological Sciences 11 13%
Neuroscience 7 8%
Biochemistry, Genetics and Molecular Biology 6 7%
Nursing and Health Professions 5 6%
Other 12 14%
Unknown 11 13%

Attention Score in Context

This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 October 2014.
All research outputs
#1,076,175
of 8,000,214 outputs
Outputs from Vascular Health and Risk Management
#44
of 404 outputs
Outputs of similar age
#27,060
of 175,613 outputs
Outputs of similar age from Vascular Health and Risk Management
#3
of 16 outputs
Altmetric has tracked 8,000,214 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 404 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 175,613 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.